Bioventus (BVS) reported fiscal Q2 adjusted earnings Wednesday of $0.22 per diluted share, up from $0.21 a year earlier.

Analysts polled by FactSet expected $0.22.

Revenue for the three months ended June 27 was $153.2 million, up from $147.7 million a year earlier.

Analysts expected $155.4 million.

The company reiterated its full-year 2026 adjusted EPS guidance of $0.75 to $0.79 and revenue of $600 million to $610 million.

Analysts expect $0.78 and $605.3 million, respectively.

Shares of Bioventus were up more than 12% in Wednesday trading.

Price: 15.09, Change: +1.67, Percent Change: +12.44